Eli Lilly and Co (LLY.US) Donanemab scores again: Japan approved, accelerating the expansion of the global Alzheimer's disease treatment market.
Eli Lilly and Co announced on Tuesday that its Alzheimer's drug donanemab has been approved by the Japan Ministry of Health, Labor and Welfare.
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
Eli Lilly and Company (NYSE:LLY) Is Largely Controlled by Institutional Shareholders Who Own 88% of the Company
Roche Narrows Pipeline to 11 Disease Areas Amidst Weight Loss Push - WSJ
Novo CEO Faces Sen. Sanders in Drug Price Showdown -- Barrons.com
Novo Nordisk CEO Set to Defend Ozempic, Wegovy Prices on Capitol Hill